MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer.

Beatriz German Sarah Abou Alaiwi Kun-Lin Ho Jagpreet S Nanda Marcos A S Fonseca Deborah L Burkhart Anjali V Sheahan Hannah E Bergom Katherine L Morel Himisha Beltran Justin H Hwang Matthew L Freedman Kate Lawrenson Leigh Ellis

Published in: Cancer research communications (2024)

Prostate cancers that escape therapy targeting the androgen receptor signaling pathways via phenotypic plasticity are currently untreatable. Our study identifies MYBL2 as a MR-TF in phenotypic plastic prostate cancer and implicates CDK2 inhibition as a novel therapeutic target for this most lethal subtype of prostate cancer.

Keyphrases

prostate cancer
radical prostatectomy
signaling pathway
cell cycle
gene expression
stem cells
magnetic resonance imaging
genome wide
computed tomography
bone marrow
mesenchymal stem cells
transcription factor
drug delivery
pi k akt
cell therapy